- drug was
created and
initially developed by
BioVex, Inc. and was
continued by Amgen,
which acquired BioVex in 2011. It was one of the
first oncolytic immunotherapy...
-
enrolled patients with
breast or
prostate cancer. 2011: In May,
Amgen acquired BioVex,
developer of
Imlygic (talimogene laherparepvec). In December,
Amgen and...
- him to
establish the
robotics company Complex Matters. In
January 2011,
BioVex, a
cancer vaccines company spun-out of UCL in 1999, was sold to
Amgen for...
-
present endeavour and has
likely been discontinued. A
private company called BioVex began Phase I
clinical trials for ImmunoVEX,
another proposed vaccine, in...
- drug was
created and
initially developed by
BioVex, Inc. and was
continued by Amgen,
which acquired BioVex in 2011. It was the
first oncolytic virus approved...
- to
reverse the
effects of
neurological diseases. In 1998,
Evans founded Biovex, a
company which specialised in the
development of a
genetically modified...
-
known as 'OncoVEX GM-CSF'. It was
developed by
BioVex Inc. (Woburn, MA, USA & Oxford, UK)
until BioVex was
purchased by
Amgen in
January 2011. It is a...
- very
effective in
eliminating tumours, most
notably so far
OncoVEX GM-CSF (
BioVex Inc, Woburn, MA)
which is in
Phase 3
clinical trials for melanoma. These...
